ConcussionORCANCT07709936
Oculomotor Rehabilitation After Concussion in Adults: A Feasibility Study
A study testing Oculomotor exercises delivered in virtual reality in people with Concussion, run by University Health Network, Toronto at 1 site in Canada.
Trial summary
After concussion, many individuals experience vision-related symptoms such as blurred vision, difficulty reading, and discomfort in visually stimulating environments, which can interfere with return to work, school, and daily activities. Read more about this study
- Who is it for?
- Ages 18 to 42 years
- Conditions the study is for
- Concussion
- What is being tested?
- Oculomotor exercises delivered in virtual reality
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteCanada
- Study dates
- 6 May 2024to 1 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 42 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adults (18 to 42 years of age) with a diagnosis of a concussion by a medical doctor between 30 days and 12 months prior
- Endorsed oculomotor related symptoms indicated by rating "moderate" or "severe" blurred-vision, double vision and/or light sensitivity.
- Normal stereopsis (depth perception) as measured with the Stereo Fly Test
- Equal (within one line difference) visual acuity between eyes as measured with the Snellen Eye Chart (Snellen, 1892) (corrected, as applicable)
- Intact extraocular movements and visual fields
- Pupils equal, round, and reactive to light and accommodation
- Healthy fundoscopic findings
- Ability to read and communicate in English
Who cannot join
- Diagnosed eye disease (i.e. glaucoma)
- Visual acuity less than 20/80 measured using the Snellen Eye Chart
- Severe neurocognitive deficits expected to interfere with participation
- Residence more than 100 km from the study site
Trial locations and contacts
1 site in 1 country.
About this study
After concussion, many individuals experience vision-related symptoms such as blurred vision, difficulty reading, and discomfort in visually stimulating environments, which can interfere with return to work, school, and daily activities. Oculomotor rehabilitation (OMR) is used by some clinicians to address these symptoms, but there is limited high-quality evidence to support its use. Prior to conducting a fully powered randomized controlled trial, it is necessary to determine whether such a study is feasible. This study aims to evaluate the feasibility of conducting a randomized trial comparing a six-week OMR program to usual care in adults with concussion. Adults aged 18 to 42 years who sustained a concussion 30 days to 12 months prior and report symptoms suggestive of oculomotor impairment will be recruited from an outpatient concussion clinic at the University Health Network and the community in Toronto, Ontario. Participants will be randomized to either a six-week OMR program consisting of weekly 60-minute clinic visits using head-mounted eye-tracking technology with prescribed home exercises, or usual care consisting of education and symptom management strategies. Feasibility outcomes will include recruitment rate, retention, perceived benefit of the OMR intervention, and safety (adverse events). Outcomes will be assessed at baseline and after six weeks. The findings will inform the design and implementation of a future trial evaluating the effectiveness of oculomotor rehabilitation after concussion.
Read the detailed description
Background Concussion is a common form of mild traumatic brain injury (mTBI) that produces a broad and heterogeneous range of symptoms and functional deficits affecting daily activities including work, school, sport, and social participation. Recovery is highly individualized and influenced by injury characteristics, personal medical history (e.g., anxiety, migraine history), and biological sex and sociocultural gender. Over 50% of individuals from the general population experience symptoms beyond four weeks. In mixed-mechanism populations, mean time to recovery is approximately 6.5 weeks for females and 5.5 weeks for males, suggesting that females may experience a longer symptom course following concussion.
Among the most prevalent clinical profiles of concussion are symptoms attributable to oculomotor dysfunction. Functional deficits in saccades, smooth pursuits, vergence, and pupillary light reflex occur far more frequently than structural injuries, making them a feasible and clinically important rehabilitation target. These deficits can manifest as blurred vision, dizziness, light sensitivity, eye strain, and difficulty tolerating visually busy environments, with downstream impacts on return to work, school, and sport. Without directed rehabilitation, these symptoms often persist.
Oculomotor rehabilitation (OMR) aims to retrain impaired eye movement functions through targeted, restitutive exercise protocols. A systematic review conducted by the study team demonstrated improvements in near point of convergence, reading rate, and visual search and attention following OMR; however, certainty of evidence was rated as low due to methodological limitations, small sample sizes, and variability in protocols. Since that review, additional studies have been published strengthening the evidence base, though existing randomized controlled trials have focused predominantly on adolescents and young adults, limiting generalizability to older adult populations.
Interest in virtual reality (VR)-based OMR delivery has grown substantially. A recent scoping review identified 10 studies using VR for post-concussion vestibular rehabilitation, reporting good tolerability and greater participant enjoyment relative to traditional approaches. To the investigators' knowledge, no published study has systematically examined the feasibility, acceptability, or perceived benefit of delivering OMR via head-mounted VR goggles combined with mobile application-based home exercise programming in adults with persisting oculomotor deficits post-concussion.
Biological sex and sociocultural gender differences in concussion reporting, symptom experience, and recovery have been documented, yet sex and gender have not been adequately explored in the context of OMR. This trial is designed to collect sex-disaggregated data to inform future research in this area.
Objectives The primary objective is to assess the feasibility of a future fully powered RCT, operationalized across four a priori criteria: recruitment, retention, adherence, and technology reliability.
The secondary objective is proof-of-concept, operationalized a priori as participant-rated perceived benefit (0-4 scale) at study completion.
Study Design This is a feasibility RCT with two parallel intervention groups, a 1:1 allocation ratio, conducted at Toronto Rehabilitation Institute (TRI)-University Health Network (UHN), Ontario, Canada.
Recruitment Participants are recruited through hospital- and community-based concussion clinics, community-based brain injury organizations, and social media platforms. Individuals who participated in prior research at the Hull-Ellis Concussion and Research Clinic, had not recovered, and had indicated willingness to be contacted for future eligible studies are also approached. Interested individuals undergo telephone-based screening followed by in-person confirmation of visually based eligibility criteria. Written informed consent is obtained prior to enrolment.
Eligibility
- Adults (18 to 42 years of age) with a diagnosis of a concussion by a medical doctor between 30 days and 12 months prior
- Endorsed oculomotor related symptoms indicated by rating "moderate" or "severe" blurred-vision, double vision and/or light sensitivity.
- Normal stereopsis (depth perception) as measured with the Stereo Fly Test
- Equal (within one line difference) visual acuity between eyes as measured with the Snellen Eye Chart (Snellen, 1892) (corrected, as applicable)
- Intact extraocular movements and visual fields
- Pupils equal, round, and reactive to light and accommodation
- Healthy fundoscopic findings
- Ability to read and communicate in English
Exclusion Criteria:
- Diagnosed eye disease (i.e. gloucoma)
- Visual acuity less than 20/80
- Severe neurocognitive deficits expected to interfere with participation
- Residence more than 100 km from the study site.
Baseline Measures Baseline data include demographics, medical history, injury characteristics, and the following validated questionnaires: Brain Injury Visual Symptom Survey (BIVSS), Convergence Insufficiency Symptoms Survey (CISS), RPQ, Patient Health Questionnaire-9 (PHQ-9), Fatigue Severity Scale (FSS), Insomnia Severity Index (ISI), Sheehan Disability Scale (SDS), Traditional Masculinity and Femininity Scales (TMS/TFS), and the Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ). Clinical assessments include near point of convergence break (NPC, in centimeters) and critical flicker fusion (CFF, in hertz).
Interventions Oculomotor Rehabilitation (OMR) Group: Participants receive six weekly in-person sessions of progressive, personalized OMR delivered via head-mounted VR goggles (FOVE) using NeuroFlex software, targeting saccades, smooth pursuits, vergence, gaze stability, optokinetic reflex, and anti-saccades. Sessions increase progressively in difficulty and duration based on individual tolerance. Between sessions, participants complete daily home-based eye movement exercises via a study-specific mobile application, targeting at least 10 minutes per day, five days per week.
Usual Care (UC) Group: Participants receive education on visual symptom-limiting strategies (e.g., pacing, screen modification). No active or sham intervention is provided.
Randomization and Allocation Participants are randomized 1:1 to OMR or UC following consent, using a blinded, sex-stratified randomization schema with variable block sizes generated a priori. Blinding of participants and study personnel after allocation is not possible given the nature of the intervention.
Outcome Measures Primary Feasibility Outcomes are assessed against a priori traffic light criteria (Green/Amber/Red) and include: recruitment rate, randomization rate, compliance to allocated arm, and retention rate.
Additional Feasibility Outcomes include: magnitude of co-intervention, VR tolerability, homework participation, study experience rating (0-4), technology reliability, and the ability of the technology to capture change in oculomotor metrics between baseline and final assessment.
Secondary Outcome: Participant-rated perceived benefit (0-4) at study completion.
Data Analysis Descriptive statistics are used to summarize feasibility outcomes and participant characteristics. The study is not powered for efficacy testing and between-group comparisons are not emphasized. Variability estimates will inform power calculations for a future full-scale RCT. Data are captured in REDCap and analyzed in SPSS (Version 25). A missing data threshold of 5% is set a priori, with complete case analysis below this threshold and multiple imputation applied above it.
Findings from this feasibility trial will be used to inform the design of a future fully powered pragmatic RCT. Feasibility metrics including recruitment and retention rates, compliance to allocated arm, and technology reliability, will be evaluated against a priori traffic light criteria to determine whether, and under what conditions, progression to a full trial is warranted. Variability estimates across candidate clinical outcomes and review of recent published literature will additionally inform outcome selection and power analysis planning for the future trial.
- Conditions
- Concussion
- Being tested
- Usual Care, Oculomotor exercises delivered in virtual reality
- Keywords
- Concussion, Virtual reality, Brain injury, Vision, Oculomotor, Adult
- Medical subject headings
- Brain Concussion, Brain Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Usual CareOther
The UC group is education only and consists of education on visual symptom-limiting strategies and resources. These include strategies such as pacing and taking breaks during visual work, strategies to modify a visual stimulus such as increasing font size on a mobile application or changing to dark mode. An active or 'sham' is not provided.
Oculomotor exercises delivered in virtual realityOther
Participants engage in eye movement training based on the following movements:
- Saccade: The ability of the eyes to shift the center of gaze quickly and accurately between targets, for example in reading
- Anti-saccade: An eye movement that is made in the opposite direction of a visual stimulus
- Smooth pursuit: A slow tracking eye movement, designed to keep a moving stimulus on the retina
- Pursuit head free: A complex, coordinated movement where both the eyes and the head move to follow a single, slow-moving object
- Optokinetic reflex: Involuntary eye movements that are triggered when watching an object moving through a visual field. It combines smooth pursuit in one direction, and a quick saccade back
- Vergence: Disjunctive movements of the eyes (convergence or divergence) that align the fovea of each eye with targets located at different distances from the observer.
Between study visits, participants compete home based exercises on a smart phone or tablet.
| Study group | Role | What they receive |
|---|---|---|
| Virtual reality based oculomotor intervention | Experimental | Participants receive 6 sessions of OMR delivered in virtual reality. Each session consists of oculomotor based trainings that increase in difficulty and duration each session. The intervention will be delivered over 6 weeks. Receives: Other: Oculomotor exercises delivered in virtual reality |
| Usual Care | Other | Education on visual symptom management. Receives: Other: Usual Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of Recruitment
Defined as the ability to recruit at least 32 individuals over a 12 month period.
Measured: 12 months
Perceived Benefit of the Intervention by Participants Allocated to OMR.
Perceived benefit of OMR in contributing to improvement in symptoms of concussion of at least 85% as measured on a scale of 0-4 (0 no benefit to 4 significant benefit) as reported after participating in 6 weekly sessions of OMR. Measured at final testing for participants in the OMR group.
Measured: Measured at final testing (8 weeks post enrollement).
Completion Rate of at Least 85%
The percentage of participants completing all study requirements including: Baseline data collection, the assigned intervention, and final testing. The assigned intervention as described in the intervention section.
Measured: At study completion (approximately 8 weeks per participant).
Harms or Adverse Events
No harms or adverse events (undesirable or unintended medical occurrence experienced by a study participant, regardless of whether it is directly caused by the intervention) reported by any participant from baseline through final testing, including during and immediately after intervention.
Measured: From enrolment to final testing at 8 weeks post enrolment.
Secondary outcomes (9)
Randomization Rate
The proportion of eligible participants who enrolled and were randomized out of the total number of individuals interested in the study.
Measured: Over the 12-month recruitment period.
Compliance to Allocated Treatment Arm
The proportion of participants who adhered to their assigned arm allocation (no withdrawals or crossovers) through study completion.
Measured: Over 6 week intervention period, measured at final testing 8 weeks post enrollment.
Magnitude of Co-intervention
Frequency and nature of non-study rehabilitation or therapeutic interventions participants engaged in during the study period, as self-reported.
Measured: Throughout the 6-week intervention period.
Tolerance to VR-based Assessment and Training
Measured using the Simulator Sickness Questionnaire (SSQ; Kennedy et al., 1993), a 16-item scale (0=not at all, 3=severe) oculomotor and nausea related symptoms.
Measured: Immediately after each weekly OMR intervention session; (for 6 weeks).
Homework Participation
Number of days participants reported completing at-home eye movement exercises (out of 5 days per week, excluding weekends).
Measured: Measured weekly over the 6-week intervention period.
Study Experience Rating
Overall perceived experience with the study rated on a 0-4 scale (0=negative, 2=neutral, 4=positive)
Measured: Measured once after final testing (8 weeks post enrollment).
Technology Reliability
Frequency of technology failures during VR delivery requiring rescheduling or session interruption.
Measured: At each participant visit over the entire study period (approximately 16 months).
Oculomotor Metrics Capture
The ability of the VR platform to capture clinically meaningful change in oculomotor parameters (saccade latency, smooth pursuit gain, vergence amplitude) between baseline and final testing.
Measured: From baseline to final testing 8 weeks post enrollment.
BIVSS Feasibility as Primary Outcome
Participant completion rates and variance estimates of the Brain Injury Visual Symptom Survey (BIVSS, score range 0-112; higher=worse symptomology) to inform power calculations for a future trial.
Measured: Baseline and final testing (8 weeks post-randomization)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study start6 May 2024
- Primary completion12 Jul 2025
- Study completion1 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ConcussionStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Collaborators
- University of Toronto, Mitacs
- Responsible party
- Sponsor
- Investigators
- Tatyana Mollayeva, MD, PhD, Principal investigator, KITE University Health Network
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07709936
- Sponsor's protocol ID
- 23-5303
- Acronym
- ORCA
- Status last verified
- Feb 2026
- First submitted
- 4 May 2026
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data underlying results reported in peer-reviewed publications will be made available upon reasonable request to the principal investigator. Informed consent obtained from all participants includes clauses permitting the sharing and secondary use of de-identified data for future research purposes. Requests for data access will be evaluated on a case-by-case basis. Data sharing will be approved where the proposed use has been reviewed and approved by an independent ethics review committee and the trial sponsor. Requestors will be required to submit a brief proposal outlining the intended research purpose, analytic plan, and data security measures. Shared data will be de-identified in accordance with established standards to minimize the risk of participant re-identification prior to transfer. Data will not be shared in any form that could reasonably be used to identify individual participants. Execution of a data use agreement will be completed.
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oculomotor Rehabilitation After Concussion in Adults: A Feasibility Study
- ClinicalTrials.gov ID
- NCT07709936
- Acronym / sponsor ID
- ORCA / 23-5303
- Conditions
- Concussion
- Keywords
- Concussion, Virtual reality, Brain injury, Vision, Oculomotor, Adult
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Collaborators
- University of Toronto, Mitacs
- Study start
- 6 May 2024 (actual)
- Primary completion
- 12 Jul 2025 (actual)
- Study completion
- 1 Sep 2025 (actual)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
After concussion, many individuals experience vision-related symptoms such as blurred vision, difficulty reading, and discomfort in visually stimulating environments, which can interfere with return to work, school, and daily activities. Oculomotor rehabilitation (OMR) is used by some clinicians to address these symptoms, but there is limited high-quality evidence to support its use. Prior to conducting a fully powered randomized controlled trial, it is necessary to determine whether such a study is feasible. This study aims to evaluate the feasibility of conducting a randomized trial comparing a six-week OMR program to usual care in adults with concussion. Adults aged 18 to 42 years who sustained a concussion 30 days to 12 months prior and report symptoms suggestive of oculomotor impairment will be recruited from an outpatient concussion clinic at the University Health Network and the community in Toronto, Ontario. Participants will be randomized to either a six-week OMR program consisting of weekly 60-minute clinic visits using head-mounted eye-tracking technology with prescribed home exercises, or usual care consisting of education and symptom management strategies. Feasibility outcomes will include recruitment rate, retention, perceived benefit of the OMR intervention, and safety (adverse events). Outcomes will be assessed at baseline and after six weeks. The findings will inform the design and implementation of a future trial evaluating the effectiveness of oculomotor rehabilitation after concussion.
Detailed description
Background Concussion is a common form of mild traumatic brain injury (mTBI) that produces a broad and heterogeneous range of symptoms and functional deficits affecting daily activities including work, school, sport, and social participation. Recovery is highly individualized and influenced by injury characteristics, personal medical history (e.g., anxiety, migraine history), and biological sex and sociocultural gender. Over 50% of individuals from the general population experience symptoms beyond four weeks. In mixed-mechanism populations, mean time to recovery is approximately 6.5 weeks for females and 5.5 weeks for males, suggesting that females may experience a longer symptom course following concussion.
Among the most prevalent clinical profiles of concussion are symptoms attributable to oculomotor dysfunction. Functional deficits in saccades, smooth pursuits, vergence, and pupillary light reflex occur far more frequently than structural injuries, making them a feasible and clinically important rehabilitation target. These deficits can manifest as blurred vision, dizziness, light sensitivity, eye strain, and difficulty tolerating visually busy environments, with downstream impacts on return to work, school, and sport. Without directed rehabilitation, these symptoms often persist.
Oculomotor rehabilitation (OMR) aims to retrain impaired eye movement functions through targeted, restitutive exercise protocols. A systematic review conducted by the study team demonstrated improvements in near point of convergence, reading rate, and visual search and attention following OMR; however, certainty of evidence was rated as low due to methodological limitations, small sample sizes, and variability in protocols. Since that review, additional studies have been published strengthening the evidence base, though existing randomized controlled trials have focused predominantly on adolescents and young adults, limiting generalizability to older adult populations.
Interest in virtual reality (VR)-based OMR delivery has grown substantially. A recent scoping review identified 10 studies using VR for post-concussion vestibular rehabilitation, reporting good tolerability and greater participant enjoyment relative to traditional approaches. To the investigators' knowledge, no published study has systematically examined the feasibility, acceptability, or perceived benefit of delivering OMR via head-mounted VR goggles combined with mobile application-based home exercise programming in adults with persisting oculomotor deficits post-concussion.
Biological sex and sociocultural gender differences in concussion reporting, symptom experience, and recovery have been documented, yet sex and gender have not been adequately explored in the context of OMR. This trial is designed to collect sex-disaggregated data to inform future research in this area.
Objectives The primary objective is to assess the feasibility of a future fully powered RCT, operationalized across four a priori criteria: recruitment, retention, adherence, and technology reliability.
The secondary objective is proof-of-concept, operationalized a priori as participant-rated perceived benefit (0-4 scale) at study completion.
Study Design This is a feasibility RCT with two parallel intervention groups, a 1:1 allocation ratio, conducted at Toronto Rehabilitation Institute (TRI)-University Health Network (UHN), Ontario, Canada.
Recruitment Participants are recruited through hospital- and community-based concussion clinics, community-based brain injury organizations, and social media platforms. Individuals who participated in prior research at the Hull-Ellis Concussion and Research Clinic, had not recovered, and had indicated willingness to be contacted for future eligible studies are also approached. Interested individuals undergo telephone-based screening followed by in-person confirmation of visually based eligibility criteria. Written informed consent is obtained prior to enrolment.
Eligibility
- Adults (18 to 42 years of age) with a diagnosis of a concussion by a medical doctor between 30 days and 12 months prior
- Endorsed oculomotor related symptoms indicated by rating "moderate" or "severe" blurred-vision, double vision and/or light sensitivity.
- Normal stereopsis (depth perception) as measured with the Stereo Fly Test
- Equal (within one line difference) visual acuity between eyes as measured with the Snellen Eye Chart (Snellen, 1892) (corrected, as applicable)
- Intact extraocular movements and visual fields
- Pupils equal, round, and reactive to light and accommodation
- Healthy fundoscopic findings
- Ability to read and communicate in English
Exclusion Criteria:
- Diagnosed eye disease (i.e. gloucoma)
- Visual acuity less than 20/80
- Severe neurocognitive deficits expected to interfere with participation
- Residence more than 100 km from the study site.
Baseline Measures Baseline data include demographics, medical history, injury characteristics, and the following validated questionnaires: Brain Injury Visual Symptom Survey (BIVSS), Convergence Insufficiency Symptoms Survey (CISS), RPQ, Patient Health Questionnaire-9 (PHQ-9), Fatigue Severity Scale (FSS), Insomnia Severity Index (ISI), Sheehan Disability Scale (SDS), Traditional Masculinity and Femininity Scales (TMS/TFS), and the Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ). Clinical assessments include near point of convergence break (NPC, in centimeters) and critical flicker fusion (CFF, in hertz).
Interventions Oculomotor Rehabilitation (OMR) Group: Participants receive six weekly in-person sessions of progressive, personalized OMR delivered via head-mounted VR goggles (FOVE) using NeuroFlex software, targeting saccades, smooth pursuits, vergence, gaze stability, optokinetic reflex, and anti-saccades. Sessions increase progressively in difficulty and duration based on individual tolerance. Between sessions, participants complete daily home-based eye movement exercises via a study-specific mobile application, targeting at least 10 minutes per day, five days per week.
Usual Care (UC) Group: Participants receive education on visual symptom-limiting strategies (e.g., pacing, screen modification). No active or sham intervention is provided.
Randomization and Allocation Participants are randomized 1:1 to OMR or UC following consent, using a blinded, sex-stratified randomization schema with variable block sizes generated a priori. Blinding of participants and study personnel after allocation is not possible given the nature of the intervention.
Outcome Measures Primary Feasibility Outcomes are assessed against a priori traffic light criteria (Green/Amber/Red) and include: recruitment rate, randomization rate, compliance to allocated arm, and retention rate.
Additional Feasibility Outcomes include: magnitude of co-intervention, VR tolerability, homework participation, study experience rating (0-4), technology reliability, and the ability of the technology to capture change in oculomotor metrics between baseline and final assessment.
Secondary Outcome: Participant-rated perceived benefit (0-4) at study completion.
Data Analysis Descriptive statistics are used to summarize feasibility outcomes and participant characteristics. The study is not powered for efficacy testing and between-group comparisons are not emphasized. Variability estimates will inform power calculations for a future full-scale RCT. Data are captured in REDCap and analyzed in SPSS (Version 25). A missing data threshold of 5% is set a priori, with complete case analysis below this threshold and multiple imputation applied above it.
Findings from this feasibility trial will be used to inform the design of a future fully powered pragmatic RCT. Feasibility metrics including recruitment and retention rates, compliance to allocated arm, and technology reliability, will be evaluated against a priori traffic light criteria to determine whether, and under what conditions, progression to a full trial is warranted. Variability estimates across candidate clinical outcomes and review of recent published literature will additionally inform outcome selection and power analysis planning for the future trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Virtual reality based oculomotor intervention | Experimental | Other: Oculomotor exercises delivered in virtual realityParticipants receive 6 sessions of OMR delivered in virtual reality. Each session consists of oculomotor based trainings that increase in difficulty and duration each session. The intervention will be delivered over 6 weeks. |
| Usual Care | Other | Other: Usual CareEducation on visual symptom management. |
Who may qualify
- Ages
- 18 to 42 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Adults (18 to 42 years of age) with a diagnosis of a concussion by a medical doctor between 30 days and 12 months prior
- Endorsed oculomotor related symptoms indicated by rating "moderate" or "severe" blurred-vision, double vision and/or light sensitivity.
- Normal stereopsis (depth perception) as measured with the Stereo Fly Test
- Equal (within one line difference) visual acuity between eyes as measured with the Snellen Eye Chart (Snellen, 1892) (corrected, as applicable)
- Intact extraocular movements and visual fields
Key exclusion criteria (4 listed)
- Diagnosed eye disease (i.e. glaucoma)
- Visual acuity less than 20/80 measured using the Snellen Eye Chart
- Severe neurocognitive deficits expected to interfere with participation
- Residence more than 100 km from the study site
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Usual CareThe UC group is education only and consists of education on visual symptom-limiting strategies and resources. These include strategies such as pacing and taking breaks during visual work, strategies to modify a visual stimulus such as increasing font size on a mobile application or changing to dark mode. An active or 'sham' is not provided. | Other | Usual Care |
| Oculomotor exercises delivered in virtual realityParticipants engage in eye movement training based on the following movements: * Saccade: The ability of the eyes to shift the center of gaze quickly and accurately between targets, for example in reading * Anti-saccade: An eye movement that is made in the opposite direction of a visual stimulus * Smooth pursuit: A slow tracking eye movement, designed to keep a moving stimulus on the retina * Pursuit head free: A complex, coordinated movement where both the eyes and the head move to follow a single, slow-moving object * Optokinetic reflex: Involuntary eye movements that are triggered when watching an object moving through a visual field. It combines smooth pursuit in one direction, and a quick saccade back * Vergence: Disjunctive movements of the eyes (convergence or divergence) that align the fovea of each eye with targets located at different distances from the observer. Between study visits, participants compete home based exercises on a smart phone or tablet. | Other | Virtual reality based oculomotor intervention |
Primary outcome
Feasibility of Recruitment
Time frame: 12 months
Defined as the ability to recruit at least 32 individuals over a 12 month period.
Perceived Benefit of the Intervention by Participants Allocated to OMR.
Time frame: Measured at final testing (8 weeks post enrollement).
Perceived benefit of OMR in contributing to improvement in symptoms of concussion of at least 85% as measured on a scale of 0-4 (0 no benefit to 4 significant benefit) as reported after participating in 6 weekly sessions of OMR. Measured at final testing for participants in the OMR group.
Completion Rate of at Least 85%
Time frame: At study completion (approximately 8 weeks per participant).
The percentage of participants completing all study requirements including: Baseline data collection, the assigned intervention, and final testing. The assigned intervention as described in the intervention section.
Harms or Adverse Events
Time frame: From enrolment to final testing at 8 weeks post enrolment.
No harms or adverse events (undesirable or unintended medical occurrence experienced by a study participant, regardless of whether it is directly caused by the intervention) reported by any participant from baseline through final testing, including during and immediately after intervention.
9 secondary outcomes
Randomization Rate
Time frame: Over the 12-month recruitment period.
Compliance to Allocated Treatment Arm
Time frame: Over 6 week intervention period, measured at final testing 8 weeks post enrollment.
Magnitude of Co-intervention
Time frame: Throughout the 6-week intervention period.
Tolerance to VR-based Assessment and Training
Time frame: Immediately after each weekly OMR intervention session; (for 6 weeks).
Homework Participation
Time frame: Measured weekly over the 6-week intervention period.
Study Experience Rating
Time frame: Measured once after final testing (8 weeks post enrollment).
Technology Reliability
Time frame: At each participant visit over the entire study period (approximately 16 months).
Oculomotor Metrics Capture
Time frame: From baseline to final testing 8 weeks post enrollment.
BIVSS Feasibility as Primary Outcome
Time frame: Baseline and final testing (8 weeks post-randomization)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data underlying results reported in peer-reviewed publications will be made available upon reasonable request to the principal investigator. Informed consent obtained from all participants includes clauses permitting the sharing and secondary use of de-identified data for future research purposes. Requests for data access will be evaluated on a case-by-case basis. Data sharing will be approved where the proposed use has been reviewed and approved by an independent ethics review committee and the trial sponsor. Requestors will be required to submit a brief proposal outlining the intended research purpose, analytic plan, and data security measures. Shared data will be de-identified in accordance with established standards to minimize the risk of participant re-identification prior to transfer. Data will not be shared in any form that could reasonably be used to identify individual participants. Execution of a data use agreement will be completed.
Related trials for Concussion
Enrolling by invitationPhase 1
Pilot Safety and Exploratory Efficacy of PSC-05 for the Treatment of Chronic Mild Traumatic Brain Injury
Mild Traumatic Brain Injury
Recruiting
Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)
Sleep Architecture, Mild Traumatic Brain Injury
Active, not recruiting
Pilot TMS in Mild TBI
Persistent Post Concussive Headache, Mild Traumatic Brain Injury
Recruiting
Non-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline
Mild Traumatic Brain Injury, Post Concussion Syndrome
Enrolling by invitation
Improving In-hospital and Post-discharge Patient Education for Mild Traumatic Brain Injury
Concussion, Mild, Traumatic Brain Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tatyana Mollayeva, MD, PhD principal investigator
KITE University Health Network
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Oculomotor exercises delivered in virtual reality in people with Concussion, run by University Health Network, Toronto at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of Recruitment (time frame: 12 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.